Success Story: Thanks To Our Assistance and Direct Premium Service, A Visiting Fellow (Postdoc) from India Secured EB1A Success Despite RFE
Client’s Testimonial:
“Thanks very much for all your help.”
On November 14th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Visiting fellow (Postdoc) in the Field of Protein Aggregation (Approval Notice).
General Field: Protein Aggregation
Position at the Time of Case Filing: Visiting fellow (Postdoc)
Country of Origin: India
State of Residence at the Time of Filing: Montana
Approval Notice Date: November 14th, 2025
Processing Time: 3 months, 28 days (Premium Processing Requested)
Case Summary:
We are pleased to share the outstanding success of a biotechnology researcher whose I-140 EB-1A petition was approved after receiving a Request for Evidence (RFE), reaffirming the exceptional significance of this individual’s scientific contributions. With support from the North America Immigration Law Group (NAILG), the petition secured approval through premium processing, demonstrating both the strength of the evidence and the national importance of the client’s work.
The client holds a Ph.D. and M.Sc. in Biotechnology and is an established expert in protein aggregation research. Within this broad scientific domain, the client stands among the small group of leading specialists in protein aggregation inhibition, diagnostic assay development for Parkinson’s disease, and the structural analysis of prion amyloids.
The client’s work focuses on understanding how amyloid formation initiates and progresses and on identifying novel methods to inhibit these harmful processes. This research provides foundational insights needed to develop early diagnostic tools and therapeutic strategies for disorders such as Parkinson’s disease, Alzheimer’s disease, and related protein misfolding conditions. By addressing urgent gaps in biomedical science and public health, the client’s contributions align directly with national priorities in disease prevention and healthcare advancement.
Filed under the EB-1A category, the petition highlighted a remarkable record of achievement, including:
- 61 peer-reviewed journal articles, including 15 as first or co-first author, and 2 book chapters, demonstrating sustained and independent research contributions.
- 4,164 citations to the client’s published work, reflecting widespread influence across biomedical, pharmaceutical, and clinical research communities.
- At least 190 completed peer reviews, underscoring the client’s recognized expertise and trusted judgment among leading scientific journals.
- Funding from India’s Council of Scientific and Industrial Research, a respected national research institution, further validates the significance and competitiveness of the client’s work.
To reinforce the petition, NAILG included four strong recommendation letters written by independent experts in the field. These experts emphasized the essential role the client’s work plays in advancing global understanding of amyloid-related diseases and developing safer, more effective biomedical interventions.
“Given the increasing number of affected patients and the subsequent strain on the healthcare system, his ongoing research is vital for ensuring the quality of public health and its early diagnostic capabilities.”
Even though an RFE was issued, NAILG’s carefully developed response successfully addressed all USCIS concerns by demonstrating the client’s extraordinary impact, original scientific contributions, and influence on the broader research community. The ultimate approval of the EB-1A petition confirms USCIS’s recognition of the client as an individual who has risen to the top of the field and whose continued research work is of substantial benefit to the United States.
We are honored to have supported this exceptional scientist and look forward to the continued contributions the client will make toward improving diagnostic tools, therapeutic development, and the nation’s broader biomedical research capabilities.